Suppr超能文献

调节性 T 细胞移植物含量增加与造血干细胞移植预后改善相关:系统评价。

Increased regulatory T cell graft content is associated with improved outcome in haematopoietic stem cell transplantation: a systematic review.

机构信息

NHS Blood and Transplant, Oxford, UK.

Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

出版信息

Br J Haematol. 2017 Feb;176(3):448-463. doi: 10.1111/bjh.14433. Epub 2017 Jan 17.

Abstract

Allogeneic haematopoietic stem cell transplant (HSCT) recipients are at increased risk of morbidity and mortality, often due to the development of acute or chronic graft-versus-host disease (GVHD). Low numbers or proportions of regulatory T cells (Tregs) have been reported in patients who develop GVHD. We undertook a systematic review of studies that reported the Treg composition of HSCT grafts in patients with haematological malignancies. Fourteen eligible studies were identified, eight of which stratified patients by Tregs (absolute dose or ratio to CD3+ or CD4+ cells). Meta-analyses showed that high levels of Tregs in the grafts were associated with improved overall survival [hazard ratio (HR) 0·42, 95% confidence interval (CI) 0·23-0·74, P = 0·003, 2 studies], with a significant reduction in non-relapse mortality (HR 0·30, 95% CI 0·14-0·64, P = 0·002, 2 studies) and a reduced risk of acute GVHD (relative risk (RR) 0·59, 95% CI 0·40-0·89, P = 0·01, 6 studies). The consistency of these findings strongly suggests that the Treg composition of HSCT grafts has a powerful effect on the success of allogeneic HSCT. The major challenge is to translate these findings into better selection of allografts and future donors to provide a substantial improvement in allogeneic HSCT outcomes and practice.

摘要

异基因造血干细胞移植 (HSCT) 受者的发病率和死亡率较高,这通常是由于急性或慢性移植物抗宿主病 (GVHD) 的发展所致。有报道称,发生 GVHD 的患者的调节性 T 细胞 (Treg) 数量或比例较低。我们对报道血液恶性肿瘤患者 HSCT 移植物中 Treg 组成的研究进行了系统评价。确定了 14 项符合条件的研究,其中 8 项根据 Treg(绝对剂量或与 CD3+或 CD4+细胞的比例)对患者进行分层。荟萃分析表明,移植物中高水平的 Treg 与总体生存率提高相关 [风险比 (HR) 0·42,95%置信区间 (CI) 0·23-0·74,P=0·003,2 项研究],非复发死亡率显著降低 [HR 0·30,95%CI 0·14-0·64,P=0·002,2 项研究],急性 GVHD 的风险降低 [相对风险 (RR) 0·59,95%CI 0·40-0·89,P=0·01,6 项研究]。这些发现的一致性强烈表明 HSCT 移植物的 Treg 组成对异基因 HSCT 的成功具有强大的影响。主要挑战是将这些发现转化为更好地选择同种异体移植物和未来供体,从而大大改善异基因 HSCT 的结果和实践。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验